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Abstract
Background: The present study sought to evaluate the usefulness of EBUS-TBNA in the diagnosis of locoregional
recurrence of lung cancer in a cohort of lung cancer patients who were previously treated surgically, and describe
our initial experience of EUS-B-FNA in this clinical scenario.
Methods: We retrospectively studied the clinical records of all patients with a previous surgically-treated lung
cancer who were referred to our bronchoscopy unit after suspicion of locoregional recurrence. The diagnostic
sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and overall accuracy of
EBUS-TBNA for the diagnosis of locoregional recurrence were evaluated.
Results: Seventy-three patients were included. EBUS-TBNA confirmed malignancy in 40 patients: 34 confirmed
to have locoregional recurrence, six had metachronous tumours. Of the 33 patients with non-malignant EBUS-TBNA;
2 had specific non-malignant diseases, 26 underwent radiological follow up and 5 patients underwent surgery. Of the
26 patients who had radiological follow up; 18 remained stable, three presented thoracic radiological progression and
5 presented extrathoracic progression. Of the 5 patients who underwent surgery; 3 had metachronous tumours, one
confirmed to be a true negative and one presented nodal invasion. Seven patients underwent EUS-B-FNA, four
of them confirmed to have recurrence. The sensitivity, specificity, NPV, PPV and overall accuracy of EBUS-TBNA
for the diagnosis of locoregional recurrence were 80.9, 100, 69.2, 100 and 86.6% respectively.
Conclusions: EBUS-TBNA is an accurate procedure for the diagnosis of locoregional recurrence of surgically-treated
lung cancer. EUS-B-FNA combined with EBUS-TBNA broads the diagnostic yield of EBUS-TBNA alone.
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Background
Lung cancer is the leading cause of cancer-related mor-
tality worldwide [1]. Surgery resection with a curative
intent is the most effective treatment for early stage
non-small- cell lung cancer (NSCLC). However, even
after complete surgical resection, the rate of recurrence
for stages I to III of NSCLC range from 30 to 70% [2]
with a high incidence of recurrence during the first
2 years. Based on this concern, published practice guide-
lines recommend multidisciplinary clinical and radio-
graphic follow up of patients with resected lung cancer
[3]. More specifically, the American College of Chest
Physicians recommends that in patients who underwent
a curative-intent surgical resection of a NSCLC, a chest
computer tomography (CT) should be performed every
6 months for the first 2 years after resection and every
year thereafter. In many cases, surgical treatment must
be combined with adjuvant chemotherapy and/or radio-
therapy which can cause inflammation and fibrosis of
the mediastinum. Furthermore, most of lung cancer
patients are smokers who may have Chronic Obstructive
Pulmonary Disease (COPD) or other inflammatory lung
disorders which may result in infectious complications.
These circumstances such as inflammation, fibrosis and
infectious complications could be presented as both lung
parenchymal abnormalities and mediastinal nodal enlarge-
ment in thoracic CT that can be misdiagnosed as regional
recurrence [4]. Thereby, mediastinal and/or hilar nodal
enlargement in the thoracic CT during follow up are com-
mon features that usually represent a challenge for the
clinician. Positron emission tomography with computer
tomography (PET/CT) has been used as a diagnostic tool
for recurrence, with a high sensitivity value [5, 6]. How-
ever, both CT and PET/CT have shown high false-positive
rates and therefore histological confirmation is mandatory
to rule out regional recurrence.
Mediastinoscopy has been demonstrated to be useful
in the assessment of recurrence in patients with previous
surgically-treated lung cancer [7]. However, mediastinos-
copy becomes more difficult, unsafe and useless after
previous thoracic surgery, especially in patients who
have been treated with induction radiotherapy. Further-
more, recurrence can lay on hilar nodes that are not
amenable for biopsy by means of mediastinoscopy.
Endobronchial ultrasound-guided transbronchial nee-
dle aspiration (EBUS-TBNA) is a minimum invasive pro-
cedure currently proposed as the first choice in the
mediastinal nodal staging of lung cancer [8]. Adding
endoscopic ultrasound fine needle aspiration (EUS-FNA)
to EBUS-TBNA has revealed higher diagnostic yield
than using EBUS-TBNA alone, due to the complemen-
tary access for different nodal stations by each technique
[9]. The evaluation of mediastinal nodes from the
esophagus using a convex probe EBUS (EUS-B-FNA)
associated to EBUS-TBNA has proven to be useful,
with figures similar to those using combination of EUS
and EBUS-TBNA [10]. The applications of EUS-B-FNA
further than lung cancer staging have been barely
investigated [11–13].
Some previous studies have demonstrated the useful-
ness of EBUS-TBNA in the diagnosis of recurrence in
patients with previously treated lung cancer [14–18].
However, some of these studies included short series of
subjects or included patients not surgically treated. The
aim of our study was to evaluate the usefulness of
EBUS-TBNA in the diagnosis of locoregional lung can-
cer recurrence in a larger cohort of subjects entirely
composed of surgically-treated patients and describe our
initial experience of EUS-B-FNA in this clinical scenario.
Methods
Patients
We conducted a single-center, retrospective study that
included all patients with a previous surgically-treated
lung cancer who were referred to our bronchoscopy unit
after suspicion of locoregional recurrence from January
2006 to October 2014. Recurrence suspicion was based
on hilar or mediastinal lymph node enlargement on CT
scan (>10 mm in the short axis on CT) and/or abnormal
nodal fludeoxyglucose (FDG) avidity on PET-CT during
follow up with or without pulmonary node/s or mass/es.
The medical records of all patients were reviewed and
clinical characteristics were introduced in a database.
EBUS-TBNA
EBUS was performed at an out-patient setting using a
flexible bronchoscope [BFUC180F, Olympus Optical Co
Ltd., Tokyo, Japan] with a distal probe capable of produ-
cing linear parallel scans of both mediastinal and peri-
bronchial tissues also a working channel suited for the
performance of TBNA under direct ultrasound guidance.
Local anesthesia and sedation were achieved using top-
ical lidocaine spray and intravenous midazolam, propofol
and/or fentanyl in accordance with the standard recom-
mendations [19]. Identified mediastinal and lobar nodes
with short-axis diameter of 5 mm or more were targeted
under direct ultrasound visualization with a 22-gauge
cytology needle specially designed for EBUS-TBNA
[NA-201SX-4022, Olympus Optical Co Ltd.]. After pass-
ing through the bronchoscope channel, the needle was
pushed out of the sheath and inserted into the tracheal
or bronchial wall under ultrasound guidance. At the tar-
get tissue, the needle tip was located, and then it was
pushed forth and back with application of negative pres-
sure using a syringe (with 10-mL suction) connected to
the proximal end of the catheter. Finally, the suction was
ceased while withdrawing the needle out of the target
structure. Samples were labeled according to their
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origin, whether it was a normal node showing lympho-
cytic cells and no neoplastic cells, or a metastatic node
showing neoplastic cells. Aspirates containing only iso-
lated dysplastic, bronchial, esophageal or blood cells or
necrotic tissue were considered inadequate. Nodal sam-
pling was targeted and nodes with high suspicion of
malignancy (enlarged on CT scan and/or abnormal FDG
avidity) were firstly sampled. If rapid on site examination
confirmed malignancy the procedure was then finished.
In case of a non malignant result, suspicious nodes were
sampled three times before ruling out malignancy and a
complete systematic sampling (including both lower
paratracheal, and subcarinal stations) was performed.
EUS-B-FNA
In cases with lesions that were inaccessible through
EBUS-TBNA (nodal stations 5, 8 or 9) the patient
underwent directly EUS-B-FNA. In cases with lesions
accessible through EBUS-TBNA the patient firstly
underwent EBUS-TBNA. If the lesion was partially visible
through EBUS-TBNA and located in a station accessible
through EUS-B-FNA then the patient underwent EUS-B-
FNA in a single-session procedure. EUS-B-FNA was per-
formed guiding the bronchoscope through the pharynx
and advanced into the esophagus under gentle pressure.
The sampling method did not differ to that previously
described for EBUS-TBNA.
Pathology
The aspirated material in the needle was recovered and
the specimens were placed on slides and fixed with 95%
ethanol. The slides were stained for one minute with
haematoxylin for rapid on-site evaluation. Papanicolau
staining with orange A and eosin was done later in the
pathology laboratory. The cytologist classified satisfac-
tory nodal samples as “normal tissue negative for malig-
nancy” when the sample contained 40 lymphocytes per
high-power field in cellular areas of the smear and/or
clusters of pigmented macrophages and no neoplastic
cells, or as “metastatic” when recognizable groups of
malignant cells were present [20]. Nodes containing only
isolated dysplastic, bronchial, esophageal or blood cells or
necrotic tissue were considered as non-representative of
the targeted structure, and were classified as inadequate.
Cell blocks were obtained and processed from the speci-
mens recovered whenever extra material was available
after the preparation of a minimum of four slides.
Definitions
Cases in which EBUS-TBNA demonstrated malignant
nodes with the same histology as the previous treated
lung cancer were considered as recurrence (true positive)
and no confirmatory tests were required. Cases in which
EBUS-TBNA demonstrated specific benign diseases were
considered as true negative and no confirmatory tests
were carried out. Cases where EBUS-TBNA demonstrated
lymphocytes without malignant cells (negative EBUS-
TBNA) underwent confirmatory surgery as a “gold
standard” or radiological follow up. Negative EBUS-
TBNA was considered true negative if the surgical
procedures did not demonstrate nodal malignancy or if
remained stable during radiological follow up for
12 months. Negative EBUS-TBNA were considered
false negative if the surgical procedures demonstrated
nodal malignancy or if radiological progression was
proved by CT. Patients that presented with extrathoracic
progression that required chemotherapy and/or could not
complete 12 months of radiological follow up were also
considered false negative. Although diagnostic yield of
EBUS-TBNA for global malignancy included patients with
metachronous tumours, outcomes of these patients were
not used in evaluating diagnostic yield of EBUS-TBNA for
locoregional recurrence. Metachronous tumours were
defined by Martini et al. [21] as follows: 1) Different histo-
logical type from the primary tumour or 2) Same histo-
logical type if: a) Free interval between tumours is at least
2 years or b) Origin from carcinoma in situ or c) Second
cancer in different lobe or lung, but: i) No carcinoma in
lymphatics common to both, ii) No extrapulmonary
metastases at time of diagnosis.
Statistical analysis
Data was entered into a database and analyzed using SPSS
software, version 18.0 [Chicago, IL, USA]. Categorical
variables were expressed as absolute and relative fre-
quencies, continuous variables as means and standard
deviations (SD) and non-normally distributed data as
medians and interquartile ranges (IQR). The diagnostic
sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV) and overall accuracy of
EBUS-TBNA were calculated according to standard
definitions for diagnosis of both locoregional recurrence
and global malignancies, including metachronous tumors,
in patients with previous surgically-treated lung cancer.
Results
Seventy-three patients were included. Patient characteris-
tics are shown at Table 1. Previous histological subtypes of
lung cancer were predominantly squamous cell-carcinoma
and adenocarcinoma and the majority of patients had
undergone previous lobectomy. Most of the patients had a
previous systematic mediastinal nodal dissection; the
median number of dissected nodes was 14.5 per patient.
Six patients had a previous staging mediastinoscopy and
20 patients had undergone EBUS-TBNA before surgery.
Primary therapy for lung cancer included surgical resec-
tion alone in 47 patients; surgical resection followed by
chemotherapy in 16; surgical resection followed by
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radiotherapy in one patient and induction chemo radio-
therapy followed by surgical resection in 9 patients.
One patient was diagnosed as stage IV but could bene-
fit for surgical treatment after resection of the single
extrathoracic metastasis. The median time between pri-
mary surgical treatment and recurrence suspicion was
23 months. CT findings were mediastinal nodal en-
largement alone in 50 patients and mediastinal nodal
enlargement with lung nodes/masses in 23 patients.
EBUS-TBNA confirmed malignancy in 40 patients
while in the remaining 33 did not show malignancy
(Fig. 1). The entire 40 patient with malignant nodes were
presented with the same histological type as the previous
treated lung cancer. However, six patients were considered
as metachronous disease instead of recurrence. Of the 34
patients confirmed to have recurrence by EBUS-TBNA,
15 patients underwent chemotherapy, 3 radiotherapy, 14
concurrent chemoradiotherapy and 2 patients received
best supportive care. In most of the cases, nodal recur-
rence affected ipsilateral hilar or mediastinal nodes and, in
20% recurrence affected contralateral mediastinum (N3).
Eleven malignant lymph nodes (8 hilars, 3 paraesophageal
stations), collected from 10 patients who resembled 29.4%
of all recurrent patients diagnosed by EBUS-TBNA, were
out of the reach of mediastinoscopy.
Of the 33 patients with non-malignant EBUS-TBNA,
two had a specific non-malignant disease diagnosed by
EBUS-TBNA (1 nodal tuberculosis, 1 foreign body reac-
tion). Of the other 31 patients, 26 patients underwent
radiological follow up and 5 patients underwent surgery.
Of the 5 patients that underwent surgery one patient
with isolated lymphadenopathies underwent mediasti-
noscopy which showed normal lymph tissue and thereby
was considered as true negative; the other 4 patients that
presented node or mass associated to the nodal enlarge-
ment underwent lobectomy: 3 patients had a final diagnosis
of metachronous lung cancer without nodal involvement
while one other patient presented a N1 positive interlobar
node in the lobectomy resection sample and thus was con-
sidered as a false negative of the EBUS-TBNA.
Of the 26 patients who had radiological follow up 18
patients remained stable after 12 months, three pre-
sented with thoracic radiological progression and 5 pa-
tients presented with extrathoracic progression and died
before completing 12 months of follow-up and thereby
were considered false negative.
Seven patients underwent EUS-B-FNA because the
lesion was difficult to be accessed (one 2R station node,
one 4 L station node) or inaccessible for EBUS (five
paraesophageal (8) stations) (Table 2, Fig. 2). Of the 2
patients with a lesion accessible by means of EBUS-
TBNA both had an EBUS-TBNA before the EUS-B-FNA
in a single-session procedure while the 5 patients with
lesions not reachable by means of EBUS-TBNA directly
underwent EUS-B-FNA. EUS-B-FNA confirmed the
recurrence in four cases. There were no major complica-
tions related to EBUS-TBNA.
The sensitivity, specificity, negative predictive value,
positive predictive value and overall accuracy of EBUS-
TBNA for the diagnosis of locoregional recurrence in
patients with previous surgically-treated lung cancer were
80.9, 100, 69.2, 100 and 86.6% respectively. The sensitivity,
specificity, negative predictive value, positive predictive
value and overall accuracy of EBUS-TBNA for the diagno-
sis of global malignancy, including metachronous tu-
mours, in patients with previous surgically-treated lung
cancer were 81.6, 100, 72.7, 100 and 87.6% respectively.
Discussion
Locoregional recurrence represents a significant problem
in lung cancer, which corresponds to a quarter of recur-
rences after surgery [22]. Reported rates of locoregional
Table 1 Patients’ characteristics
Gender: Male (67/73 (91.7%))
Age: Mean 69 (SD ± 10.4).
Time to recurrence: 23 (IQR: 11.5–49).
CT findings:
Isolated mediastinal lymphadenopaties: 50 (68.5%)












Wedge resection 14 (19.2%)
Systematic mediastinal nodal dissection:
Linfadenectomy: 58 (79.5%)
Nodes diseccted: 14.5 (IQR: 11–20.75)
Stations diseccted: 4.5 (±1)
Previous mediastinoscopy: 6 (8.2%)
Previous EBUS: 20 (27.4%)
Previous treatment:
Surgery 47 (64.4%)
Adyuvant chemotherapy 16 (21.9%)
Adyuvant radiotherapy 1 (1.4%)
Trimodal treatment 9 (12.3%)
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recurrence of NSCLC after surgery vary widely in litera-
ture due to the heterogeneity of the studies, as some of
them including small sample sizes, variable disease
stages, differences in follow up time and unclear defini-
tions of recurrence versus metachronous tumours.
Locoregional recurrences typically occur rapidly, as
nearly 90–95% of all local recurrences develop during
the first five years after the initial surgery [23]. Patho-
logical stage, surgical technique (wedge resection or seg-
mentectomy versus full lobar resection) and patients’
characteristics have been demonstrated to be independent
predictors of recurrence. Although postoperative sur-
veillance programs have not established a survival
benefit, most guidelines recommend follow up of
patients after curative-intent surgery. In our series,
half of the patients were presented with nodal local
recurrence, 6.8% extrathoracic metastases and 12%
metachronous lung cancer, confirming that the likeli-
hood of malignancy in these patients is high and thus the
diagnosis and clinical-decision making cannot rely only on
image-based explorations.
Before EBUS-TBNA, mediastinoscopy was the most
used diagnostic method as an invasive approach to
explore the mediastinum. However, few studies have
focused on the role of mediastinoscopy in the diagnosis
of locoregional recurrence. The concept of “complex”
mediastinum refers to an altered fibrotic mediastinum
secondary to previous thoracic surgery (primary medias-
tinoscopy or nodal dissection) or induction therapy [24].
Although some studies performed by expert surgeons in
referral hospitals have shown good accuracy of reme-
diastinoscopy, with complication rates similar to primary
mediastinoscopy [25], remediastinoscopy is not widely
used due to concerns about safety and usefulness [26].
In our series, one third of the patients had concurrent
radiotherapy and/or chemotherapy and 7 patients had a
previous mediastinoscopy. Regarding the diagnosis of
local lymph node recurrence, only one patient required
mediastinoscopy after an EBUS. This particular patient
73 patients 





























Fig. 1 aExcluded for analysis of recurrence. bMediastinoscopy showing normal lymph tissue. cOne patient with malignant N1 interlobar node in
the resection specimen. dOne tuberculosis, one foreign body reaction
Table 2 EBUS procedure
Total nodes sampled: 213
Nodes sampled (per patient): 2.92 (SD ± 2.2)
Stations sampled (per patient): 2 (SD ± 1.2)
Malignant nodesa: 45
Mediastinal: 37
2 L: 1 2R: 1
4R: 7 4 L: 11
7: 14
8 L: 2 8 L: 1
Hilar: 8
10 L: 1 10R: 2
11 L: 2 11R: 3
Mean sizeb: 14.8 (IQR: 11.5–18.4)
Esophagus (EUS-B-FNA): 7 (9.6%)




aIn patients with recurrence diagnosed by EBUS-TBNA
bIn mm (short-axis diameter)
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neither underwent previous mediastinoscopy nor
received neo/adjuvant therapy. The mediastinoscopy
showed no malignancy and the patient remained stable
in subsequent radiological follow up. In our series,
almost one third of the patients with recurrence con-
firmed by EBUS-TBNA presented with nodes out of the
reach of mediastinoscopy: 3 patients presented with
paraesophageal lesions and 7 patients had hilar lesions.
One of the advantages of EBUS-TBNA is its ability to
sample hilar nodes. Probably this advantage has not been
properly emphasized. One possible explanation is that
EBUS-TBNA has been mainly used for mediastinal sta-
ging of lung cancer where hilar involvement is not rele-
vant enough since contralateral hilar N3 involvement
without N3 mediastinal affection is not very frequent
and the distinction between N0/N1, although has im-
portance in the prognosis and the choice of treatment,
rarely affects the surgical indication. Nevertheless, the
evaluation of N1 nodes is crucial in patients undergoing
sublobar resection or local tissue-sparing treatments such
as brachytherapy, radiofrequency ablation and stereotactic
body radiation. These are the only therapeutic options to
many patients who cannot benefit from conventional sur-
gical intervention, including those with previous surgical
treatment like in our series. In our study the only surgical
false negative case presented with N1 interlobar node.
The reported sensibility for EBUS-TBNA in the diagnosis
of N1 disease is lower than that described for N2 staging
[27], mainly because the size of the convex probe EBUS in
many cases does not permit to reach N1 nodes beyond
station 11. However, this issue could be solved with the
development of new thinner convex probe EBUS.
Recently, Wada et al. [28] described their first experience
with a new thin convex probe echobronchoscope [BF-
Y0046 Olympus Medical Systems Corp] with a thinner tip
(5.9 mm) and a larger bending angle than conventional
convex probe ecobronchoscopes. These authors reported
an improved accessibility to the distal airways in a porcine
model, suggesting that thinner echobronchoscopes would
increase the diagnostic yield of N1 nodes (especially those
beyond the hilum) and peripheral nodes/masses.
Endoscopic ultrasound with a convex probe ultrasonic
bronchoscope (EUS-B-FNA) was first described in 2009
[10]. EUS-B-FNA broads the diagnostic yield of EBUS-
Fig. 2 Four cases of recurrence diagnosed by EUS-B-FNA: Case 1 (a, b, c): a 68-years old man with a stage IIA squamous-cell carcinoma in LLL
treated by means of lobectomy presented a pleural effusion on the first CT control 6 months after the surgery, the PET/CT showed a high uptake
on a 8 left station node, an EUS-B-FNA confirmed recurrence. Case 2 (d): a 55-years old man with a previous stage IA NSCLC-NOS in RUL treated
by means of wedge resection presented an 8 left lymphadenopathy on the first CT control 6 months after the surgery. Case 3 (e): a 40-years old
man with a carcinoid on middle lobe treated by means of RLL and ML bilobectomy presented a mass/nodal enlargement on right 8 station that
invaded the pulmonary veins, the diagnosis was consistent with atypical carcinoid. Case 4 (f, g): a 71-year old man with a stage IIA adenocarcinoma in
RUL treated by means of lobectomy presented a 2R adenopathy in a CT 21 months before the surgery. Although being a paratracheal node
the approach was easier through the esophagus
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TBNA alone because it allows the approach of nodal sta-
tions that are not in contact with the tracheobronchial
wall (stations 5 and lower mediastinal stations: 8, 9) and
also increases the access to nodes that could be better
achieved through the esophagus. Moreover EUS-B-FNA
is also better tolerated and safer in patients with respira-
tory impairment. Although these advantages, EUS-B-
FNA requires a learning period before systematically
employed, as the endobronchial references are lost on
the white light image and the ultrasonographic anatomy
boundaries vary from the endobronchial view. In our
series, ten percent of the patients underwent EUS-B-
FNA, and 4 patients (12.9%) with recurrence diagnosed
by EBUS-TBNA were exclusively diagnosed by EUS-B-
FNA (3 in paraesophageal stations and one in 2R station).
In our study, some nodes although located on subcarinal
or paratracheal stations, were more easily reached by the
esophagus (Fig. 2) due the post-surgical changes in the
mediastinal architecture. Few studies have described the
usefulness of EUS-B-FNA apart from lung cancer staging.
Szlubowski et al. [11] published their experience with
EUS-B-FNA combined with EBUS-TBNA in the lung can-
cer restaging after induction therapy and other two studies
described the usefulness of EUS-B-FNA in the sampling
of left adrenal gland in patients with lung cancer [12, 13].
To our knowledge this is the first study in which EUS-B-
FNA has been used in the diagnosis of locoregional lung
cancer recurrence.
Although the interpretation of the visualized medias-
tinal structures after surgery is more difficult than in a
naïve mediastinum, our study demonstrates excellent
diagnostic performance of EBUS-TBNA in the diagnosis
of locoregional recurrence of patients with surgically
treated lung cancer. Our results are similar to those
reported for new developed lung cancer staging and also
comparable to those to previous studies that included
shorter series of surgically-treated patients. Yamamoto et
al. [17] in a series of 40 surgically-treated patients
showed a sensitivity and NPV of 100%, while Han et al.
[16] in a series of 42 surgically-treated patients showed a
sensitivity of 94.3% and a NPV of 77.8%. Other studies
that included non-surgically-treated patients [14, 15, 18]
also demonstrated a high diagnostic accuracy of EBUS-
TBNA in the diagnosis of lung cancer recurrence. Thus,
changes in the mediastinal anatomy in a post-surgical
mediastinum do not affect the diagnostic yield of EBUS-
TBNA procedure. Remarkably, in another situation of
“complex” mediastinum, following induction therapy,
EBUS-TBNA showed lower diagnostic value in restaging
of lung cancer [29, 30]. This is probably not due to the
procedure itself, but because of complexity in the inter-
pretation of the pathological samples. It has been previ-
ously reported that aspirates from malignant nodes
treated with chemotherapy may content less cellular
burden that could have necrotic tissue, making the
pathologic interpretation more difficult.
Conclusions
EBUS-TBNA is proved to be an accurate, safe and
minimally invasive procedure in the diagnosis of locore-
gional recurrence of surgically-treated lung cancer and
should be considered as a first choice in patients with
radiological abnormalities during follow up. EUS-B-FNA
demonstrates to be useful in patients with locoregional
lung cancer recurrence, not only in stations not reachable
by EBUS-TBNA, but also in paratracheal nodes that could
be better attained by the esophagus, whenever there are
changes in the normal mediastinal architecture.
Abbrevations
COPD: Chronic obstructive pulmonary disease; CT: Computed tomography;
EBUS-TBNA: Endobronchial ultrasound transbronchial-guided needle aspiration;
EUS-B-FNA: Endoscopic ultrasound fine-needle aspiration using an
echobronchoscope; EUS-FNA: Endoscopic ultrasound fine-needle aspiration;
FDG: Fludeoxyglucose; IQR: Interquartilic range; NPV: Negative predictive value;
NSCLC: Non-small cell lung cancer; PET/CT: Positron emission tomography/
Computed tomography; PPV: Positive predictive value; SD: Standard deviation
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